<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/02ECE3B0-F864-4593-BCE9-348E204E2058"><gtr:id>02ECE3B0-F864-4593-BCE9-348E204E2058</gtr:id><gtr:name>MRC National Inst for Medical Research</gtr:name><gtr:address><gtr:line1>The Ridgeway</gtr:line1><gtr:line2>Mill Hill</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>NW7 1AA</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/3D91E107-4414-4C76-8846-46B6F6E45BD5"><gtr:id>3D91E107-4414-4C76-8846-46B6F6E45BD5</gtr:id><gtr:firstName>Kenneth</gtr:firstName><gtr:surname>Raj</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U117573807"><gtr:id>9D54B99E-93A8-4512-8DFA-666D0EDEF692</gtr:id><gtr:title>Studies on the Life Cycle of the Human Papillomavirus</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U117573807</gtr:grantReference><gtr:abstractText>The association between Human Papillomavirus (HPV) infection and cervical cancer is well established. While HPVs by themselves cannot cause cancer, their continued presence increases the risk of such a development, and as infectious agents, their spread within the population augments the potential problem considerably. Efforts to contain and eventually abolish this virus are concentrated at two fronts. The first is the development of a vaccine against HPV, which has been a recent success, and the second is to develop anti-viral drugs to eliminate viruses that have already gained access into the cervical tissue. To address the latter, one needs to first understand how HPVs infect, replicate and persist in the tissue for years. Hence we have elected to study and be well acquainted with these processes which constitute the life-cycle of this virus with the tenet that this knowledge may provide channels to intervene and to rid tissues of this pathogen. While it is difficult to be certain whether continued presence of HPV DNA is due to persistence or continuous infections, it is nevertheless possible (and important) to determine the mechanism/s employed by HPV to remain in the host tissue for prolonged periods, if not indefinitely.</gtr:abstractText><gtr:technicalSummary>The association between viral infection and human diseases is well established. Among them is the link between viruses and cancers. While viruses by themselves cannot cause cancer, their continued presence increase the risk of such a development, and as infectious agents, their spread within the population augments the potential problem considerably. The human papillomavirus (HPV) plays a very significant role in causing cancer of the cervix among women. It is hoped that the availability of vaccine against HPV will decrease the incidences of cervical cancers in years to come. However, a sizeable fraction of women who are already infected, but repeatedly fail to clear the virus in spite of having high amounts of antibodies against HPV, are unlikely to benefit from this vaccine. This group of women, together with those in countries that cannot afford an HPV vaccination programme, will continue to live with a high risk of developing cervical cancer. This short-fall necessitates that a therapy be made available to tackle HPV infection at stages after the virus has infected the host cells in the cervix. This approach which we are embarking upon requires that we first understand (1) what are the target cells of this virus (2) how HPVs establish and maintain themselves in the target cells for prolonged periods of time, and (3) how they avoid being detected by the immune systems of hosts. Using our ability to produce infectious papillomaviruses in the laboratory, coupled with the technology to separate epidermal stem cells from non-stem cells, we will investigate the outcome of HPV infection of stem cells and non-stem cells of the cervix. Firstly, we will assess whether HPVs ability to infect these cell sub-types are similar. Secondly, we will investigate whether the immortalising capacity of HPV is similar between them. We will also investigate what viral genes are expressed at the early stage of infection and whether viral DNA can be maintained as stably replicating episomes in both or only one of these cell sub-types. If they can, we will ascertain the mode by which the HPV DNA replicates in them. Results from these analyses will tell us whether HPVs have a predilection for stem cells as opposed to non-stem cells, and whether infection of epidermal stem cells will result in a similar or different outcome from HPV-infected non-stem cells in terms of cellular defence, cellular immortalisation, and maintenance and replication of the viral genomes. These information are necessary for us to design ways or drugs that will thwart the survival of the virus in the cervix.</gtr:technicalSummary><gtr:fund><gtr:end>2009-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2004-10-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>2251592</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5DB62221-9055-4B4C-B176-0F7A08DB4BAC</gtr:id><gtr:title>Protective mechanisms of p53-p21-pRb proteins against DNA damage-induced cell death.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d2b9d51dd22db210a4e34aab9b90852e"><gtr:id>d2b9d51dd22db210a4e34aab9b90852e</gtr:id><gtr:otherNames>Garner E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>E4EDCB09E3B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5515BC99-E5E0-4CAF-A791-94AF6F2791FE</gtr:id><gtr:title>Biology of papillomavirus replication in infected epithelium</gtr:title><gtr:parentPublicationTitle>Future Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9788e20c9b1eb2e9299cf194e44f809c"><gtr:id>9788e20c9b1eb2e9299cf194e44f809c</gtr:id><gtr:otherNames>Doorbar J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:outcomeId>10D1BABD3D3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70737648-9ADC-414E-88F3-5CEC9D53CE4F</gtr:id><gtr:title>Different modes of human papillomavirus DNA replication during maintenance.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd3e49095c214ce99d0d105e6af1f94d"><gtr:id>dd3e49095c214ce99d0d105e6af1f94d</gtr:id><gtr:otherNames>Hoffmann R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>AE6457B304B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>619E480A-9713-4140-B3A8-3675B6FE9174</gtr:id><gtr:title>HP1-beta is required for development of the cerebral neocortex and neuromuscular junctions.</gtr:title><gtr:parentPublicationTitle>The Journal of cell biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4d96a57264296ce8136ffcd960a26354"><gtr:id>4d96a57264296ce8136ffcd960a26354</gtr:id><gtr:otherNames>Aucott R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9525</gtr:issn><gtr:outcomeId>2C26B0BD176</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E408EFE6-D587-4E51-BCE3-6F8DD774EA59</gtr:id><gtr:title>Structural analysis reveals an amyloid form of the human papillomavirus type 16 E1--E4 protein and provides a molecular basis for its accumulation.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8bb1af3f013b69a2b59656152330523"><gtr:id>d8bb1af3f013b69a2b59656152330523</gtr:id><gtr:otherNames>McIntosh PB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>4100163A967</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E2A1D09-28FC-45FA-B015-429E7718F1DC</gtr:id><gtr:title>Cells with defective p53-p21-pRb pathway are susceptible to apoptosis induced by p84N5 via caspase-6.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d2b9d51dd22db210a4e34aab9b90852e"><gtr:id>d2b9d51dd22db210a4e34aab9b90852e</gtr:id><gtr:otherNames>Garner E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>990BE7636B6</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U117573807</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>